Insider activity (SEC Form 4)
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
Open-market · last 30 days:
2 buyers bought $56K
0 sellers sold $0
Open-market · last 90 days:
2 buyers bought $144K
0 sellers sold $0
| Insider | Role | Date | Transaction | Shares | Value |
|---|
| Altman Peter |
President and CEO, Director |
2026-07-17 |
Open-market buy |
500 |
$415 |
| Altman Peter |
President and CEO, Director |
2026-07-15 |
Open-market buy |
1500 |
$1K |
| Altman Peter |
President and CEO, Director |
2026-07-14 |
Open-market buy |
2800 |
$2K |
| Altman Peter |
President and CEO, Director |
2026-07-10 |
Open-market buy |
1000 |
$940 |
| Altman Peter |
President and CEO, Director |
2026-07-09 |
Open-market buy |
1000 |
$900 |
| Altman Peter |
President and CEO, Director |
2026-07-08 |
Open-market buy |
5400 |
$5K |
| Altman Peter |
President and CEO, Director |
2026-07-08 |
Open-market buy |
5500 |
$5K |
| Altman Peter |
President and CEO, Director |
2026-07-02 |
Tax withholding |
54606 |
$68K |
| GILLIS EDWARD M |
Senior Vice President, Devices |
2026-07-02 |
Tax withholding |
17269 |
$21K |
| McClung David |
Chief Financial Officer |
2026-07-02 |
Tax withholding |
23125 |
$29K |
| Altman Peter |
President and CEO, Director |
2026-06-29 |
Grant/award |
110625 |
$133K |
| GILLIS EDWARD M |
Senior Vice President, Devices |
2026-06-29 |
Grant/award |
39521 |
$47K |
| McClung David |
Chief Financial Officer |
2026-06-29 |
Grant/award |
60483 |
$73K |
| STERTZER SIMON H |
Director |
2026-06-23 |
Open-market buy |
39000 |
$39K |
| STERTZER SIMON H |
Director |
2026-06-22 |
Open-market buy |
70200 |
$65K |
| Altman Peter |
President and CEO, Director |
2026-06-18 |
Open-market buy |
800 |
$768 |
| Altman Peter |
President and CEO, Director |
2026-06-17 |
Open-market buy |
1500 |
$1K |
| Altman Peter |
President and CEO, Director |
2026-06-09 |
Open-market buy |
5000 |
$4K |
| Altman Peter |
President and CEO, Director |
2026-05-20 |
Open-market buy |
1500 |
$1K |
| Altman Peter |
President and CEO, Director |
2026-05-19 |
Open-market buy |
200 |
$190 |
Most recent 20 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.
8-K
filed 2026-06-18
confidence 72%
Item 7.01
This is a shareholder letter disclosing strategic business updates, regulatory milestones, and capital allocation plans following a recent capital raise. While it contains forward-looking statements about regulatory submissions (CardiAMP PMDA submission in Q4 2026), clinical trial enrollment, and partnership opportunities, it does not constitute a discrete material event from the taxonomy (not an earnings release, M&A activity, executive change, impairment, covenant breach, or other specific event type). The disclosure is material to investors as it outlines near-term catalysts and business strategy, but the Item 7.01 Regulation FD format and content—a strategic update rather than a specific triggering event—best fits "other_material."
View raw filing on EDGAR →
8-K
filed 2026-06-12
confidence 95%
Item 3.01
BioCardia received a Nasdaq delisting notice on April 10, 2026 for failing to maintain the $2.5 million minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). Although the company claims to have regained compliance through an ATM offering that raised $4.9 million in net proceeds, Nasdaq retains ongoing monitoring authority and explicitly warns that "if at the time of its next periodic report the Company does not evidence compliance, it may be subject to delisting." This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
filed 2026-06-08
confidence 95%
Item 8.01
BioCardia sold 3,509,604 shares at $1.279 per share pursuant to an "At The Market" offering agreement with H.C. Wainwright & Co. This is a classic dilutive equity issuance under an ATM facility, which materially increases share count and dilutes existing shareholders. ATM offerings are a standard disclosure category under Item 3.02, though disclosed here under Item 8.01.
View raw filing on EDGAR →
8-K
filed 2026-06-05
confidence 75%
Item 7.01
BioCardia disclosed receipt of FDA meeting minutes confirming that its ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for the CardiAMP Cell Therapy System. This is a material regulatory milestone for a clinical-stage biotech company, as FDA confirmation of trial adequacy for PMA is a significant de-risking event that would affect investor assessment of the company's path to commercialization. However, this does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M&A, impairment, or other enumerated events), warranting classification as other_material.
View raw filing on EDGAR →
8-K
filed 2026-05-28
confidence 75%
Item 7.01
BioCardia disclosed a positive Consultation Record from Japan's PMDA supporting regulatory submission for CardiAMP cell therapy for ischemic HFrEF, with clinical trial results showing positive outcomes (179-second improvement in exercise tolerance, 82% reduction in angina episodes) and no major adverse cardiac events. While this is a significant regulatory milestone affecting market opportunity (estimated 20,000 eligible patients in Japan), it does not fit neatly into the standard event taxonomy—it is neither an earnings release (no financial results), nor a material impairment, litigation, or M&A event. The disclosure is material to investors as it represents meaningful regulatory progress toward commercialization in a major market.
View raw filing on EDGAR →
8-K
filed 2026-05-21
confidence 75%
Item 7.01
BioCardia disclosed positive preliminary clinical trial results for CardiAMP Cell Therapy presented at a major medical conference (Euro PCR), showing safety (no major adverse cardiac events) and efficacy outcomes (179-second improvement in exercise tolerance, 82% reduction in angina episodes at six months through two-year follow-up). While this is clinical trial data rather than financial results or a traditional earnings release, the positive efficacy and safety findings for a lead therapeutic candidate are material to investors' assessment of the company's pipeline and commercial prospects. This does not fit neatly into the earnings_release category (which typically refers to financial results) but represents a material clinical milestone disclosure.
View raw filing on EDGAR →